company background image
ATB

AntibioticeBVB:ATB Stock Report

Market Cap

RON386.7m

7D

0.7%

1Y

16.6%

Updated

24 Nov, 2021

Data

Company Financials
ATB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance1/6
Financial Health5/6
Dividends0/6

ATB Stock Overview

Antibiotice S.A. develops and produces generic drugs in Romania.

Antibiotice Competitors

Zentiva

BVB:SCD

RON1.8b

Biofarm

BVB:BIO

RON768.6m

Merck

NYSE:MRK

US$207.8b

Sanofi

ENXTPA:SAN

€109.6b

Price History & Performance

Summary of all time highs, changes and price drops for Antibiotice
Historical stock prices
Current Share PriceRON0.58
52 Week HighRON0.59
52 Week LowRON0.48
Beta0.13
1 Month Change1.41%
3 Month Change2.49%
1 Year Change16.60%
3 Year Change17.79%
5 Year Change11.63%
Change since IPO599.13%

Recent News & Updates

Jun 08
Is Antibiotice (BVB:ATB) A Risky Investment?

Is Antibiotice (BVB:ATB) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Mar 10
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Shareholder Returns

ATBRO PharmaceuticalsRO Market
7D0.7%-2.4%-1.9%
1Y16.6%19.4%35.4%

Return vs Industry: ATB underperformed the RO Pharmaceuticals industry which returned 19.3% over the past year.

Return vs Market: ATB underperformed the RO Market which returned 33.8% over the past year.

Price Volatility

Is ATB's price volatile compared to industry and market?
ATB volatility
ATB Average Weekly Movement1.6%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement3.9%
10% most volatile stocks in RO Market6.3%
10% least volatile stocks in RO Market2.1%

Stable Share Price: ATB is less volatile than 75% of RO stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: ATB's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19551,415Ioan Nanihttps://www.antibiotice.ro

Antibiotice S.A. develops and produces generic drugs in Romania. The company’s portfolio of products comprises approximately 150 medicines for human use in 12 therapeutic classes, as well as medicines for veterinary use. It offers sterile injectable powders, capsules, tablets, ointments, gels, creams, suppositories, and active substances.

Antibiotice Fundamentals Summary

How do Antibiotice's earnings and revenue compare to its market cap?
ATB fundamental statistics
Market CapRON386.69m
Earnings (TTM)RON26.57m
Revenue (TTM)RON393.56m

14.6x

P/E Ratio

1.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ATB income statement (TTM)
RevenueRON393.56m
Cost of RevenueRON171.30m
Gross ProfitRON222.26m
ExpensesRON195.68m
EarningsRON26.57m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.04
Gross Margin56.47%
Net Profit Margin6.75%
Debt/Equity Ratio24.5%

How did ATB perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

8%

Payout Ratio

Valuation

Is Antibiotice undervalued compared to its fair value and its price relative to the market?

14.55x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: ATB (RON0.58) is trading above our estimate of fair value (RON0.11)

Significantly Below Fair Value: ATB is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ATB is good value based on its PE Ratio (14.6x) compared to the European Pharmaceuticals industry average (26.7x).

PE vs Market: ATB is poor value based on its PE Ratio (14.6x) compared to the RO market (12.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATB is good value based on its PB Ratio (0.7x) compared to the XE Pharmaceuticals industry average (3.1x).


Future Growth

How is Antibiotice forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Antibiotice has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Antibiotice performed over the past 5 years?

-3.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATB has high quality earnings.

Growing Profit Margin: ATB's current net profit margins (6.8%) are lower than last year (7.6%).


Past Earnings Growth Analysis

Earnings Trend: ATB's earnings have declined by 3.5% per year over the past 5 years.

Accelerating Growth: ATB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ATB had negative earnings growth (-2.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.6%).


Return on Equity

High ROE: ATB's Return on Equity (4.5%) is considered low.


Financial Health

How is Antibiotice's financial position?


Financial Position Analysis

Short Term Liabilities: ATB's short term assets (RON342.5M) exceed its short term liabilities (RON156.7M).

Long Term Liabilities: ATB's short term assets (RON342.5M) exceed its long term liabilities (RON94.5M).


Debt to Equity History and Analysis

Debt Level: ATB's net debt to equity ratio (23.8%) is considered satisfactory.

Reducing Debt: ATB's debt to equity ratio has increased from 13.9% to 24.5% over the past 5 years.

Debt Coverage: ATB's debt is well covered by operating cash flow (41.9%).

Interest Coverage: ATB's interest payments on its debt are well covered by EBIT (9.1x coverage).


Balance Sheet


Dividend

What is Antibiotice current dividend yield, its reliability and sustainability?

0.57%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: ATB's dividend (0.57%) isn’t notable compared to the bottom 25% of dividend payers in the RO market (2.82%).

High Dividend: ATB's dividend (0.57%) is low compared to the top 25% of dividend payers in the RO market (5.42%).


Stability and Growth of Payments

Stable Dividend: ATB is not paying a notable dividend for the RO market, therefore no need to check if payments are stable.

Growing Dividend: ATB is not paying a notable dividend for the RO market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: ATB is not paying a notable dividend for the RO market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATB's dividend in 3 years as they are not forecast to pay a notable one for the RO market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Ioan Nani (62 yo)

12.83yrs

Tenure

Mr. Ioan Nani serves as General Manager and Non-Independent Director at Antibiotice S.A. since 2009. He served as Non-Independent Vice President of Board at Antibiotice S.A., since October 2019. He served...


Leadership Team

Experienced Management: ATB's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: ATB's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Antibiotice S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Antibiotice S.A.
  • Ticker: ATB
  • Exchange: BVB
  • Founded: 1955
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: RON386.691m
  • Shares outstanding: 671.34m
  • Website: https://www.antibiotice.ro

Number of Employees


Location

  • Antibiotice S.A.
  • 1 Valea Lupului Street
  • Iasi
  • 707410
  • Romania

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/24 22:44
End of Day Share Price2021/11/24 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.